How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/philadelphia-chromosome-positive-acute-lymphoblastic-leukemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Philadelphia chromosome-positive acute lymphoblastic leukemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Philadelphia chromosome-positive acute lymphoblastic leukemia (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Philadelphia chromosome-positive acute lymphoblastic leukemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Sprycel	dasatinib	Handa Therap	dasatinib	Ephrin type-B receptor 6	2006-01-01
Gleevec	imatinib	Novartis	Kinase Inhibitor	Receptor tyrosine-protein kinase erbB-2	2001-01-01
Gleevec	Gleevec	M.D. Anderson Cancer Center		Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Handa Therap · 1 drug in Philadelphia chromosome-positive acute lymphoblastic leukemia
M.D. Anderson Cancer Center · 1 drug in Philadelphia chromosome-positive acute lymphoblastic leukemia
Novartis · 1 drug in Philadelphia chromosome-positive acute lymphoblastic leukemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Philadelphia chromosome-positive acute lymphoblastic leukemia:

Cite this brief

Drug Landscape (2026). Philadelphia chromosome-positive acute lymphoblastic leukemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/philadelphia-chromosome-positive-acute-lymphoblastic-leukemia. Accessed 2026-06-10.

Philadelphia chromosome-positive acute lymphoblastic leukemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing